Nucala (mepolizumab)

pCPA File Number: 22535
Negotiation Status:
Concluded with an LOI
Indication(s):
Add-on maintenance treatment of severe eosinophilic asthma in children (aged 6 years and older)
Sponsor/Manufacturer:
GlaxoSmithKline Inc.
CDA-AMC Project Number:
Not Applicable
pCPA Engagement Letter Issued:
Negotiation Process Concluded: